ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

ACR Convergence

Keynote Speaker Tait Shanafelt, MD

Keynote Speaker Tait Shanafelt, MD

ACR Convergence 2025, the world’s premier rheumatology experience, is underway this week (Oct. 24–29) in Chicago. This in-person event showcased cutting-edge and timely topics in rheumatology, as well as the prevention, diagnosis and treatment of rheumatic diseases and related comorbid conditions. Check out the video highlights here. Below, you’ll find links to our meeting reports, which will be updated frequently. And don’t miss our expert-curated reports on the top research in lupus nephritis and psoriatic arthritis presented at the meeting.

Focused Content

  • Lupus Nephritis FocusRheum

    Renal biopsy showing class III lupus nephritis with rare foci of subendothelial deposits (wire loop lesions).

    In this commentary by lupus expert Graciela S. Alarcón, MD, MPH, MACR, some of the many abstracts on research into lupus nephritis presented at ACR Convergence 2025 are highlighted. The abstracts selected demonstrate the advances made on the early recognition of the condition, as well as offering some hope in terms of achieving better outcomes. And don’t forget to explore our research reviews, case reports and clinical articles.


    VIEW

  • Psoriatic Arthritis FocusRheum

    What new research on psoriatic arthritis has the potential to impact patient care or future research? Expert and founding editor David S. Pisetsky, MD, PhD, a professor of medicine and integrative immunobiology at Duke University School of Medicine, Durham, N.C., and a staff rheumatologist at the Durham VA Medical Center, curated the research presented at ACR Convergence 2025 and answers that question. You’ll find his commentary and much more in this FocusRheum. 


    VIEW

Previous ACR Meetings

Complete Coverage

The Great Pediatric Debate—Corticosteroids in SLE: Slay or Stay?

Long-term use of corticosteroids is associated with numerous adverse effects, particularly in children, but guidance is lacking on how to manage low-dose prednisone in clinically quiescent disease. In The Great Debate at ACR Convergence 2025—Corticosteroids in Pediatric SLE: Slay or Stay, two pediatric lupus experts took to the stage to explore this important topic.

A Liquid Biopsy for Lupus Nephritis?

Urine biomarkers have the potential to change how lupus nephritis is managed, serving as a noninvasive means of early detection, assessing treatment response and more.

A Community Connection

Dr. Heidi Prather detailed how social prescription may aid patients with chronic diseases and the research supporting this approach to care in her keynote speech during ACR Convergence 2025.